USA flag logo/image

An Official Website of the United States Government

Antibody Prophylaxis and Therapy of Flavivirus Infection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71244
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI060217
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
L2 DIAGNOSTICS, LLC
BOX 8175 NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Antibody Prophylaxis and Therapy of Flavivirus Infection
Agency: HHS
Contract: 1R43AI060217-01
Award Amount: $969,452.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapy and prophylaxis to treat and prevent life-threatening flavivirus infections. West Nile virus is the focus of Phase I studies. Our working hypothesis is that high titer anti-envelope protein antibodies can protect humans against flaviviruses. Passive immunization is an accepted medical practice that can protect against infection. Immunizing animals with a proprietary recombinant West Nile virus envelope protein antigen induces high titer antibodies. These antibodies protect mice from a lethal dose of West Nile virus when administered i.p. to natve or infected mice. Protective anti-envelope protein antibodies will be produced using standard equine immunization and antibody purification protocols. IgG antibody, F(ab')2 and Fab administered i.v. or i.c.v will be evaluated in a mouse model of neurotropic WN virus infection. Phase I experiments will also begin developing neutralizing antibodies to related flavivirus envelope proteins. In Phase II, we expect to obtain preclinical data on an equine antibody preparation to protect humans and animals from West Nile virus infection; produce protective antibodies for related flaviviruses; and develop humanized anti-envelope protein monoclonal antibodies. This project will provide clinicians, public health officials, and veterinarians with new means to manage flavivirus virus outbreaks.

Principal Investigator:

Raymond A. Koski
2035892029
RAYMOND.KOSKI@L2DX.COM

Business Contact:

Martin Mattessich
2037371952
MJMATT@IX.NETCOM.COM
Small Business Information at Submission:

L2 DIAGNOSTICS, LLC
L2 DIAGNOSTICS, LLC BOX 8175 NEW HAVEN, CT 94904

EIN/Tax ID: 061509946
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No